TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2646753

Group type: EXPERIMENTAL
Intervention: Piroxicam (40 mg on days 1 and 2, additional 20 mg on day 3 if necessary)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Naproxen (1,000 mg on days 1 and 2, additional 500 mg on day 3 if necessary)
Number of subjects: 198
Study: 31306607

Group type: EXPERIMENTAL
Intervention: Optimized/predictive interface
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Optimized/static interface
Number of subjects: 42

Group type: COMPARATOR
Intervention: Random/static interface
Number of subjects: 42

Group type: COMPARATOR
Intervention: Random/predictive interface
Number of subjects: 42
Study: 27416774

Group type: EXPERIMENTAL
Intervention: Intentional Oblique Transection Double Stapling Technique (IOT-DST)
Number of subjects: 15
Study: 24359098

Group type: EXPERIMENTAL
Intervention: Maxillary sinus packing with epinephrine hydrochloride-soaked cotton pledgets (Group 1)
Number of subjects: 57

Group type: COMPARATOR
Intervention: No packing (Group 2)
Number of subjects: 57
Study: 23543447

Group type: COMPARATOR
Intervention: Adefovir (ADV) monotherapy
Number of subjects: 206

Group type: COMPARATOR
Intervention: Lamivudine (LAM) monotherapy
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Combined therapy (LAM + ADV)
Number of subjects: 206

Group type: COMPARATOR
Intervention: LAM group
Number of subjects: 206
Study: 20887516

Group type: EXPERIMENTAL
Intervention: Aegis Ortho® (ACP-containing orthodontic composite)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Concise® (resin-based orthodontic composite)
Number of subjects: 14
Study: 17710487

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) simulator training using Procedicus MIST, 2 hours per day for 2 days
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Box trainer training, 2 hours per day for 2 days
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group watched an educational video for 30 minutes
Number of subjects: 35
Study: 15756221

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG) plus 70% lactulose (1 mL/kg/day)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo plus 70% lactulose (1 mL/kg/day)
Number of subjects: 84
Study: 12934177

Group type: EXPERIMENTAL
Intervention: efavirenz plus indinavir
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: nelfinavir plus indinavir
Number of subjects: 517

Group type: COMPARATOR
Intervention: indinavir
Number of subjects: 517
Study: 11761737

Group type: EXPERIMENTAL
Intervention: 10-session multicomponent program (n = 25)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 5-session multicomponent program (n = 31)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 5-session multicomponent plus self-help manual program (n = 25)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: self-help-manual-only program (n = 33)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (n = 48)
Number of subjects: 114
Study: 8859237

Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg/kg bolus followed by saline infusion)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Propofol (1.0 mg/kg bolus followed by 65 micrograms/kg/min infusion)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both Midazolam and Propofol
Number of subjects: 28
Study: 8396100

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg daily for 3 days)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Amoxycillin (30 mg/kg/day for 10 days in three divided doses; children > 20 kg received 250 mg tid daily)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 154

Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 154
Study: 3523741

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg X 2)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 28795342

Group type: EXPERIMENTAL
Intervention: Cholecalciferol therapy (50,000 IU once a week for 12 weeks)
Number of subjects: 119
Study: 25125300

Group type: EXPERIMENTAL
Intervention: High-risk plaque detected by coronary CTA
Number of subjects: 472

Group type: COMPARATOR
Intervention: Significant CAD (≥50% stenosis)
Number of subjects: 472

Group type: COMPARATOR
Intervention: Clinical risk assessment (age, sex, number of cardiovascular risk factors)
Number of subjects: 472
Study: 22965507

Group type: EXPERIMENTAL
Intervention: Repeated aspiration and alcohol instillation sclerotherapy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Single-session alcohol retention sclerotherapy
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study: 20951260

Group type: EXPERIMENTAL
Intervention: Thromboelastometrically guided transfusion algorithm
Number of subjects: 56

Group type: COMPARATOR
Intervention: Routine transfusion practices (clinical judgment-guided transfusion)
Number of subjects: 56
Study: 17595270

Group type: EXPERIMENTAL
Intervention: Weight management program (Bright Bodies)
Number of subjects: 209
Study: 16164121

Group type: EXPERIMENTAL
Intervention: Vitamin C 100 mg/day
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 12078940

Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg + Amlodipine 5 mg (BZ+AM)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Captopril 50 mg + Hydrochlorothiazide 25 mg (CP+HT)
Number of subjects: 405
Study: 11008323

Group type: EXPERIMENTAL
Intervention: Glutathione (5 g immediately before cisplatin)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (2000 ml electrolyte infusion before and 2000 ml normal saline after cisplatin)
Number of subjects: 20
Study: 8536820

Group type: EXPERIMENTAL
Intervention: Voglibose 0.5 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Voglibose 1.0 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Voglibose 1.0 mg (3 times daily for 7 days)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Voglibose 2.0 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Voglibose 5.0 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 2621331

Group type: EXPERIMENTAL
Intervention: HCG injection for ovulation induction
Number of subjects: 77
Study: 859943

Group type: EXPERIMENTAL
Intervention: Daily application of INH 400 mg, rifampicin 450-600 mg, and myambutol 25 mg/kg for the first two months followed by 15 mg/kg
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Intermittent application three times weekly of INH 600 mg, rifampicin 750 mg, and myambutol 30 mg/kg for the first two months followed by 20 mg/kg
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Intermittent application twice weekly of INH 800 mg, rifampicin 900 mg, and myambutol 50 mg/kg for the first two months followed by 30 mg/kg
Number of subjects: 227

Group type: COMPARATOR
Intervention: Control group treated by daily application of Str one gram for 6-8 months, INH 5-10 mg/kg and PAS 12-15 g daily
Number of subjects: 227

Group type: COMPARATOR
Intervention: All groups (A, B1, B2) compared to classical mode of treatment
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Follow-up of all groups
Number of subjects: 227
Study: 31219898

Group type: EXPERIMENTAL
Intervention: Sacral Prophylactic Dressings (SPDs)
Number of subjects: 0
Study: 28741576

Group type: EXPERIMENTAL
Intervention: SYNERGY bioabsorbable polymer‐coated everolimus‐eluting stent
Number of subjects: 412

Group type: COMPARATOR
Intervention: PROMUS Element Plus permanent polymer‐coated everolimus‐eluting stent
Number of subjects: 412
Study: 25479982

Group type: EXPERIMENTAL
Intervention: Constant load at 25W, 50W, 75W, 100W, 125W
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Systematically varied loads (increased or decreased by steps of 25W) with overall loads kept constant at 50W, 75W, or 100W
Number of subjects: 209
Study: 22521543

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 7808
Study: 21961467

Group type: EXPERIMENTAL
Intervention: Motivational plus behavioral skills intervention (17-week program)
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Neighborhood supports for physical activity (parks, lighting)
Number of subjects: 679
Study: 19320276

Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole capsule
Number of subjects: 24
Study: 16982282

Group type: EXPERIMENTAL
Intervention: AH Plus (thick layer)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Pulp Canal Sealer (thick layer)
Number of subjects: 82

Group type: COMPARATOR
Intervention: EndoREZ (thick layer)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Sealapex (thick layer)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Pulp Canal Sealer (thin layer)
Number of subjects: 82

Group type: COMPARATOR
Intervention: EndoREZ (thin layer)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Sealapex (thin layer)
Number of subjects: 82

Group type: COMPARATOR
Intervention: AH Plus (thin layer)
Number of subjects: 82
Study: 15333432

Group type: COMPARATOR
Intervention: 0.2% ropivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.2% levobupivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.125% levobupivacaine
Number of subjects: 60
Study: 10952406

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl plaster
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sustained release morphine tablets
Number of subjects: 18
Study: 9400906

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 1533

Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Number of subjects: 1533

Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 1533
Study: 8298547

Group type: EXPERIMENTAL
Intervention: Relaxation treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Attention-control
Number of subjects: 21

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 21
Study: 3434765

Group type: EXPERIMENTAL
Intervention: Trichloroethylene
Number of subjects: 40

Group type: COMPARATOR
Intervention: Enflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Enflurane plus fentanyl
Number of subjects: 40
Study: 29175451

Group type: EXPERIMENTAL
Intervention: Electric Pudendal Nerve Stimulation (EPNS)
Number of subjects: 60
Study: 27904000

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (6 g/d for 8 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Medium chain triglycerides oil (6 g/d for 8 weeks)
Number of subjects: 34
Study: 25033743

Group type: EXPERIMENTAL
Intervention: Counselling sessions including grandmothers
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Counselling sessions excluding grandmothers
Number of subjects: 323

Group type: COMPARATOR
Intervention: No intervention, living with mother
Number of subjects: 323

Group type: COMPARATOR
Intervention: No intervention, not living with mother
Number of subjects: 323
Study: 22958441

Group type: EXPERIMENTAL
Intervention: Community health worker (CHW)‐based interpersonal communication campaign (IPC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 0
Study: 19710086

Group type: EXPERIMENTAL
Intervention: Hyaloglide
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard release (Control)
Number of subjects: 45
Study: 18279374

Group type: COMPARATOR
Intervention: BsmI-TaqI BT haplotype
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: bT haplotype
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: baT haplotype
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: BaT haplotype
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: rs1544410 polymorphism
Number of subjects: 145
Study: 16030275

Group type: EXPERIMENTAL
Intervention: Rapid feedback on quality indicators (n = 38 hospitals, 2533 patients)
Number of subjects: 5675

Group type: COMPARATOR
Intervention: Delayed feedback on quality indicators (n = 38 hospitals, 3142 patients)
Number of subjects: 5675
Study: 12603640

Group type: EXPERIMENTAL
Intervention: rizatriptan 10‐mg standard tablets
Number of subjects: 5388

Group type: EXPERIMENTAL
Intervention: rizatriptan 10‐mg orally disintegrating tablets
Number of subjects: 5388

Group type: COMPARATOR
Intervention: Oral usual care medications
Number of subjects: 5388
Study: 10334901

Group type: EXPERIMENTAL
Intervention: Radial checkerboard stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diffuse chromatic stimulus with no luminance variation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Very high spatial frequency luminance grating
Number of subjects: 0
Study: 8697550

Group type: EXPERIMENTAL
Intervention: 2M2V (mivacurium 0.15 mg.kg‐1 plus vecuronium 0.1 mg.kg‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 2V (2 x ED95 of vecuronium)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 4V (4 x ED95 of vecuronium)
Number of subjects: 30
Study: 1853859

Group type: EXPERIMENTAL
Intervention: Personalized dietary advice based on the Netherlands Nutrition Council guidelines
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 80
Study: 7049013

Group type: EXPERIMENTAL
Intervention: Fenoterol syrup
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Theophylline syrup
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo syrup
Number of subjects: 11
Study: 29551699

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Combination of IMT + FES
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 61
Study: 29431251

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 8399
Study: 27089049

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with tegafur–uracil (UFT)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Mismatch repair (MMR) status
Number of subjects: 304
Study: 24582719

Group type: EXPERIMENTAL
Intervention: Aprepitant (125mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Aprepitant (125mg) with naloxone (10mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo with naloxone (10mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Aprepitant
Number of subjects: 25
Study: 23126348

Group type: EXPERIMENTAL
Intervention: Educational Care (EC)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 188
Study: 19887192

Group type: EXPERIMENTAL
Intervention: Open VIH
Number of subjects: 145

Group type: COMPARATOR
Intervention: Laparoscopic VIH
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Patients with seromas
Number of subjects: 145

Group type: COMPARATOR
Intervention: Patients without seromas
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Seromas
Number of subjects: 145
Study: 17319428

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 10 mg + 15 microg fentanyl
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 11 mg + 15 microg fentanyl
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 12 mg + 15 microg fentanyl
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 13 mg + 15 microg fentanyl
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine 14 mg (no fentanyl)
Number of subjects: 50
Study: 15003297

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided BTX-A injections (Group A, n=8)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Blind BTX-A injections (Group B, n=7)
Number of subjects: 15
Study: 11479250

Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 1016

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1016
Study: 9595969

Group type: EXPERIMENTAL
Intervention: African American elders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education-matched groups
Number of subjects: 0
Study: 8092501

Group type: EXPERIMENTAL
Intervention: Morphine 0.1 mg/kg
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 97
Study: 3391621

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Discontinuation of treatment
Number of subjects: 30
Study: 27523397

Group type: EXPERIMENTAL
Intervention: Below-knee compression garments
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Secondary task
Number of subjects: 44
Study: 27519922

Group type: EXPERIMENTAL
Intervention: Transvaginal NOTES
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classical laparoscopy
Number of subjects: 0
Study: 24678906

Group type: EXPERIMENTAL
Intervention: Tofogliflozin 10 mg
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Tofogliflozin 20 mg
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Tofogliflozin 40 mg
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Tofogliflozin (all doses)
Number of subjects: 230
Study: 22198969

Group type: EXPERIMENTAL
Intervention: Amygdala reactivity to angry faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angry facial expressions
Number of subjects: 0
Study: 21595861

Group type: EXPERIMENTAL
Intervention: Limbal silicone oil removal (n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Pars plana silicone oil removal (n = 8)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both limbal and pars plana SOR
Number of subjects: 16

Group type: COMPARATOR
Intervention: Limbal silicone oil removal
Number of subjects: 16

Group type: COMPARATOR
Intervention: Silicone oil injection
Number of subjects: 16

Group type: COMPARATOR
Intervention: Balanced salt solution (BSS) injection
Number of subjects: 16
Study: 18511439

Group type: EXPERIMENTAL
Intervention: SPV-guided intraoperative fluid management
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 80
Study: 16359587

Group type: EXPERIMENTAL
Intervention: Osteopathic treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 32
Study: 14671164

Group type: EXPERIMENTAL
Intervention: 1 mg GH/m(2).d
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 2 mg GH/m(2).d
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 1 mg GH/m(2).d and 2 mg GH/m(2).d
Number of subjects: 75
Study: 10632908

Group type: EXPERIMENTAL
Intervention: Wis‐Hipple laryngoscope (WhL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Adult Bullard laryngoscope (BL)
Number of subjects: 50
Study: 8693230

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Computed tomography (CT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Endorectal coil magnetic resonance imaging (EMRI)
Number of subjects: 90
Study: 1643677

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (4 ml 0.5% isobaric bupivacaine)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Epidural anaesthesia (15 ml of 0.5% bupivacaine)
Number of subjects: 65
Study: 6375709

Group type: EXPERIMENTAL
Intervention: glaucine 30 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: dextromethorphan 30 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 30858257

Group type: EXPERIMENTAL
Intervention: Visit Planner (waiting room health IT tool)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 750
Study: 28422579

Group type: EXPERIMENTAL
Intervention: Bipolar disorder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Major depressive disorder
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bipolar disorder during mania
Number of subjects: 0
Study: 27238859

Group type: EXPERIMENTAL
Intervention: 1.3% liposomal bupivacaine via ultrasound-guided bilateral TAP block
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.25% non-liposomal bupivacaine with adrenaline via ultrasound-guided bilateral TAP block
Number of subjects: 60
Study: 24504577

Group type: EXPERIMENTAL
Intervention: Insoles used for ulcer prevention
Number of subjects: 60
Study: 22924353

Group type: EXPERIMENTAL
Intervention: Diamine silver fluoride/potassium iodide
Number of subjects: 19

Group type: COMPARATOR
Intervention: Oxalic acid-based preparation
Number of subjects: 19
Study: 19904816

Group type: EXPERIMENTAL
Intervention: Silicone hydrogel contact lenses
Number of subjects: 7

Group type: COMPARATOR
Intervention: Conventional hydrogel contact lenses
Number of subjects: 7
Study: 18033568

Group type: EXPERIMENTAL
Intervention: Femoral nerve block (0.50% bupivacaine hydrochloride with epinephrine 1:200,000)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 15853164

Group type: EXPERIMENTAL
Intervention: Humor interventions
Number of subjects: 0
Study: 12475448

Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 2457

Group type: COMPARATOR
Intervention: Noninvasive strategy
Number of subjects: 2457
Study: 9500624

Group type: EXPERIMENTAL
Intervention: Cyclosporine microemulsion (CsA‐ME)
Number of subjects: 1097

Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 1097
Study: 8539008

Group type: EXPERIMENTAL
Intervention: Objects presented in the same category (sequential and simultaneous trials)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Objects presented in mixed categories (sequential and simultaneous trials)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Simultaneous presentation of objects
Number of subjects: 4

Group type: COMPARATOR
Intervention: Sequential presentation of objects
Number of subjects: 4
Study: 2379297

Group type: EXPERIMENTAL
Intervention: Rheum officinale Baill
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Rheum palmatum L
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Rheum tanguticum Maxim ex Balf
Number of subjects: 312
Study: 718785

Group type: EXPERIMENTAL
Intervention: Pethidine analgesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extradural analgesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No analgesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pethidine + Extradural analgesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elective Caesarean sections
Number of subjects: 0